Mankind Pharma (MANKIND) Q4 24/25 earnings summary

Executive summary

• Celebrated 30 years of operations, now ranked 4th by value and 2nd by volume in the Indian pharma market.

• Completed major acquisition of Bharat Serums and Vaccines Limited (BSV), strengthening super-specialty and gynecology leadership, and impacting comparability with prior periods.

• Focused on organic growth, strategic acquisitions, in-licensing, and scaling specialty, super specialty, and consumer healthcare segments.

• Significant operational reforms, leadership upgrades, and field force optimization completed to drive future growth.

• Approved audited standalone and consolidated financial results for FY25, with unmodified audit opinions.

Financial highlights

• FY25 consolidated revenue: INR 12,207.44 crore, up 19% YoY; Q4 FY25 revenue: INR 3,079 crore, up 27% YoY.

• Adjusted EBITDA margin for FY25 at 25.9%; Q4 FY25 at 23.1%.

• PAT for FY25 increased to INR 2,011.12 crore; diluted EPS at INR 49.1.

• Gross margin improved by 260 bps YoY to 71.4% for FY25.

• Cash flow from operations at INR 2,413 crore; CapEx at INR 832 crore.

Outlook and guidance

• Domestic revenue expected to grow at 1.2x IPM in FY26; VSC/BSV portfolio targeted for 18%-20% growth.

• R&D investment to rise to 2.5%-3% of revenue in FY26; EBITDA margin guidance maintained at 25%-26%.

• Net debt/Adjusted EBITDA targeted at 1-1.2x by FY26, with full acquisition debt retirement by FY28.

• Management expects continued growth from BSV acquisition and international expansion, including new Sri Lanka subsidiary.

• Export sales to remain below 15% of total revenue; domestic business to remain the primary growth driver.